Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 7/20 | 0.38 |
| ▸ | F10 | P00742 | 3/20 | 0.34 |
| ▸ | MDM4 | O15151 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | MC4R | P32245 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
| ▸ | CCR1 | P32246 | 1/20 | 0.30 |
| ▸ | CCR2 | P41597 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13699661 | 0.97 | MDM2 (0.40) | MDM2F10MDM4HTR2CMC4R | |
| SCHEMBL13699551 | 0.88 | CYP3A4 (0.39) | MDM2F10HTR2CMC4RCHRM2 | |
| SCHEMBL4154815 | 0.88 | CYP3A4 (0.39) | MDM2F10HTR2CMC4RCHRM2 | |
| SCHEMBL13699630 | 0.84 | CYP3A4 (0.41) | MDM2F10MDM4HTR2CMC4R | |
| SCHEMBL13699634 | 0.79 | MDM2 (0.46) | MDM2 | |
| SCHEMBL13699651 | 0.77 | MDM2 (0.41) | MDM2 | |
| SCHEMBL4154817 | 0.76 | F10 (0.34) | F10MC4RCHRM2CHRM1 | |
| SCHEMBL13699643 | 0.72 | MDM2 (0.39) | MDM2HTR2CMC4RDRD2DRD4 | |
| SCHEMBL13699589 | 0.72 | MDM2 (0.41) | MDM2MC4RCHRM2CHRM1CCR2 | |
| SCHEMBL13699648 | 0.71 | MDM2 (0.41) | MDM2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | VERNALIS (R&D) (GB) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | CNR2, CNR1, ALK | MDM2 2997/4885F10 4002/4885MDM4 4600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.